Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMT CTN 1507)


Study Number
50517
Phase
2
Purpose

This is a Phase II, single arm, multi-center trial, designed to estimate the efficacy and toxicity of haploidentical bone marrow transplantation (BMT) in patients with sickle cell disease (SCD). Based on their age and entry criteria patients are stratified into two groups: (1) children with SCD with strokes; and (2) adults with severe SCD.

Full Title

(BMT CTN Protocol 1507) Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease

ClinicalTrials.Gov ID
NCT03263559

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.